NeoGenomics, Inc. Current Federal Tax Expense (Benefit)
NeoGenomics, Inc. (NEO) reported Current Federal Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-17
- NeoGenomics, Inc. current federal tax expense (benefit) for fiscal 2025 was $0.00.
- NeoGenomics, Inc. current federal tax expense (benefit) for fiscal 2024 was -$35.00K.
- NeoGenomics, Inc. current federal tax expense (benefit) for fiscal 2023 was $0.00.
- NeoGenomics, Inc. current federal tax expense (benefit) for fiscal 2022 was -$41.00K, a 200.00% decline from fiscal 2021.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-17 |
| 2024-12-31 | -$35.00K 10-K · filed 2026-02-17 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-17 |
| 2022-12-31 | -$41.00K 10-K · filed 2025-02-18 |
| 2021-12-31 | $41.00K 10-K · filed 2024-02-20 |
| 2020-12-31 | -$434.00K 10-K · filed 2023-02-24 |
| 2019-12-31 | -$303.00K 10-K · filed 2022-02-25 |
| 2018-12-31 | -$448.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | -$91.00K 10-K · filed 2020-02-28 |
| 2016-12-31 | -$8.00K 10-K · filed 2019-02-26 |
| 2015-12-31 | $56.00K 10-K · filed 2018-03-13 |
| 2014-12-31 | $113.00K 10-K · filed 2017-03-14 |
| 2013-12-31 | $93.00K 10-K · filed 2016-04-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |